PURPOSE: With the emergence of targeted therapies, the indications of cytoreductive nephrectomy have to be redefined. This review article presents the evidence data guiding our current indications of surgery in the management of metastatic renal cell carcinoma (mRCC) in the era of targeted therapies. METHODS: A nonsystematic review of the electronic databases PubMed and MEDLINE from 1980 to 2012 was performed and limited to English language. RESULTS: Two studies based on immunotherapy (EORTC 30947 and SWOG 8949) were at the origins of the recommendations on initial nephrectomy for patients with mRCC. Since the introduction of angiogenesis inhibitors, there is still no high-level evidence from prospective studies assessing the indication of surgery for mRCC. However, surgery still has its importance in the management of primary tumors and metastasis with the objective of an optimal balance between morbidity, quality of life, and survival. The treatment sequence between surgery and targeted therapies is still to be established and two randomized prospective studies were then specifically designed and are currently recruiting. CONCLUSIONS: Preliminary evidence data from retrospective series seem to be in favor of a benefit of surgery for patients with good and intermediate prognosis. However, patients' inclusions in current prospective studies are highly recommended to clearly precise nephrectomy's indications.
PURPOSE: With the emergence of targeted therapies, the indications of cytoreductive nephrectomy have to be redefined. This review article presents the evidence data guiding our current indications of surgery in the management of metastatic renal cell carcinoma (mRCC) in the era of targeted therapies. METHODS: A nonsystematic review of the electronic databases PubMed and MEDLINE from 1980 to 2012 was performed and limited to English language. RESULTS: Two studies based on immunotherapy (EORTC 30947 and SWOG 8949) were at the origins of the recommendations on initial nephrectomy for patients with mRCC. Since the introduction of angiogenesis inhibitors, there is still no high-level evidence from prospective studies assessing the indication of surgery for mRCC. However, surgery still has its importance in the management of primary tumors and metastasis with the objective of an optimal balance between morbidity, quality of life, and survival. The treatment sequence between surgery and targeted therapies is still to be established and two randomized prospective studies were then specifically designed and are currently recruiting. CONCLUSIONS: Preliminary evidence data from retrospective series seem to be in favor of a benefit of surgery for patients with good and intermediate prognosis. However, patients' inclusions in current prospective studies are highly recommended to clearly precise nephrectomy's indications.
Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245
Authors: Maxine Sun; Firas Abdollah; Jan Schmitges; Marco Bianchi; Zhe Tian; Shahrokh F Shariat; Kevin Zorn; Daniel Pharand; Hugues Widmer; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: BJU Int Date: 2011-09-27 Impact factor: 5.588
Authors: Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng Journal: J Urol Date: 2010-11-12 Impact factor: 7.450
Authors: Nicholas G Cost; Scott E Delacroix; Joshua P Sleeper; Paul J Smith; Ramy F Youssef; Brian F Chapin; Jose A Karam; Stephen Culp; E Jason Abel; James Brugarolas; Ganesh V Raj; Arthur I Sagalowsky; Christopher G Wood; Vitaly Margulis Journal: Eur Urol Date: 2011-02-23 Impact factor: 20.096
Authors: Jose A Karam; Brian I Rini; Leticia Varella; Jorge A Garcia; Robert Dreicer; Toni K Choueiri; Eric Jonasch; Surena F Matin; Steven C Campbell; Christopher G Wood; Nizar M Tannir Journal: J Urol Date: 2010-12-17 Impact factor: 7.450
Authors: Vincent Cloutier; Umberto Capitanio; Laurent Zini; Paul Perrotte; Claudio Jeldres; Shahrokh F Shariat; Philippe Arjane; Jean-Jacques Patard; Francesco Montorsi; Pierre I Karakiewicz Journal: Eur Urol Date: 2008-11-25 Impact factor: 20.096
Authors: Javier Puente Vázquez; T Alonso Gordoa; J Moreno; L Poma; E Diaz Rubio; A Gomez; J Blazquez; J L Gonzalez Larriba Journal: Curr Treat Options Oncol Date: 2015-03